Arrowhead, Axolabs Ink RNAi Therapeutics Services Deal
March 08, 2012
Arrowhead, Axolabs Ink RNAi Therapeutics Services Deal
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Arrowhead Offers Timeline for HBV Candidate, Plans Two Phase I Trials
February 14, 2013 / Gene Silencing News - Arrowhead Presents Preclinical Data on HBV Candidate, Subcutaneous Delivery Tech
November 8, 2012 / Gene Silencing News - Arrowhead Publishes Rodent, Primate Data on Preclinical Hepatitis B Therapy
February 28, 2013 / Gene Silencing News - Arrowhead Publishes Primate Data on Co-Delivery Approach for Cholesterol-Conjugated siRNAs
November 29, 2012 / Gene Silencing News - Arrowhead Takes Last Steps toward Moving HBV Drug into Human Testing
June 7, 2012 / Gene Silencing News